XML 155 R44.htm IDEA: XBRL DOCUMENT v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Sep. 30, 2025
Dec. 31, 2023
Jul. 07, 2017
Equity Line of Credit and Shelf Registration Statement a $20 million Equity Line of Credit ("ELOC") with Hudson Global Ventures, LLC. Our Form S-3 shelf registration statement became effective on December 8, 2025, under which the Company is registered to offer and sell up to $50,000,000 of securities from time to time. Under the ELOC, we may, at our sole discretion, draw down between $25,000 and $2,000,000 per draw, subject to applicable exchange caps. Subsequent to December 31, 2025, we made our first draw under the ELOC on February 25, 2026, issuing 180,000 shares of Common Stock at $0.5229 per share for gross proceeds of $94,130. Management believes this facility provides meaningful near-term liquidity, with capacity to provide up to approximately $4 million in the short term, subject to market conditions        
Convertible note principal outstanding $ 3,135,000        
Debt issuance costs $ 2,912,000        
Pipeline Conversion to Revenue we had ten active SIS and CES integration projects with a combined contract value of approximately $3 million, including a $500,000 signed purchase order from a global biopharmaceutical leader received in December 2025. Our broader commercial sales pipeline of management-tracked opportunities exceeded $18 million at year-end, with quoted opportunities of approximately $11 million in progress. These figures represent potential future revenue and are not committed orders or guarantees of future performance. Conversion of this pipeline is a primary driver of our 2026 liquidity plan. Our sales backlog grew during 2025 to approximately $1.8 million, reflecting improved visibility into near-term revenue conversion and continued contribution from our recurring consumables and service revenue base        
Cost Management $ 731,000        
Recorded an allowance 47,844 $ 227,000      
Total shareholders' equity 588,504 $ 4,098,939   $ 8,358,894  
Working capital 1,000,000.0        
Accumulated deficit $ (58,100,000)        
Accounts payable concentraction, percentage 42.00% 60.00%      
Net income (loss) $ (3,749,000) $ (4,477,000)      
Cash used in operations 1,197,000 1,440,000      
Cash and cash equivalents   88,000      
Recognize revenue 424,032 211,724      
Inventory Reserve 500,000 1,100,000      
Warranty Reserve 10,905 30,000      
Advertising And Promotional Expenses 114,000 221,000      
Research And Development Expenses $ 290,000 291,000      
Cash Balances At Financial Institutions   $ 250,000      
Shares of common stock outstanding 20,277,205 20,015,205      
Common Stock, Shares Authorized 250,000,000 250,000,000      
Convertible debentures          
Potentially Dilutive Securities 2,508,000 2,080,000      
Stock Options          
Common stock issuable upon vesting of restricted stock units 66,666        
Potentially Dilutive Securities 737,542 805,042      
Preferred A stock          
Potentially Dilutive Securities 63,750 63,750      
2016 Equity Incentive Plan          
Shares of common stock outstanding 6,000,000.0 5,700,000      
Common Stock, Shares Authorized         2,000,000
Common Stock, Shares Issued 60,000 60,000      
Granted restricted stock units 100,000        
Two Vendors | Cost of Sales [Member]          
Concentration Risk, In Percentage 60.00% 67.00%      
Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member]          
Granted 100,000        
Unrecognized stock-based compensation expense $ 66,553        
Weighted average exercise price, Granted $ 0.9983        
Issued shares of common stock 33,334        
RSUs vest in three equal installments 33,334 shares vested immediately upon the grant date of October 6, 2025; 33,333 shares vest on May 30, 2026; and 33,333 shares vest on May 30, 2027        
Nasdaq Listing Deficiencies          
Total shareholders' equity $ 588,504   $ 2,206,482    
Warrants          
Weighted average exercise price, Granted $ 0 $ 0      
Potentially Dilutive Securities 2,604,388 2,765,846